Pulmonary Medicine / 2017 / Article / Tab 1

Clinical Study

Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients

Table 1

Patient characteristics.

Patient characteristicsUntreated (Tob−)
group (mean ± SD)
Tobramycin-treated (Tob+)
group (mean ± SD)

Age (years) (5–21) (9–46)0.01
FEV1 (% predicted) (59–131) (27–107)0.002
BMI (kg/m2) (14.5–20.5)1 (14.5–24.1)0.036
SDS-BMI (−2.9–0.9) (−2.8–0.8)ns
Liver disease1/10 (10%)4/46 (9%)ns
CFRDM0/10 (0%)5/46 (11%)ns
Serum creatinine (mg/dL)ns
eCCl Schwartz (mL/min/1.73 m2) (109–198) (92–236)ns
GFR 69–90 mL/min/1.73 m20/10 (0%)0/46 (0%)ns
eCCl Cockcroft-Gault (mL/min/1.73 m2) (70–128) (71–174)ns
GFR 69–90 mL/min/1.73 m25/10 (50%)17/46 (37%)ns
P. aeruginosa+0/10 (0%)46/46 (100%)
iv tobramycin courses0 (1–57)

Results are presented as mean ± SD (range). Untreated (Tob−) group: CF patients that never received intravenous AG antibiotics, Tobramycin-treated (Tob+) group: CF patients that received various courses of intravenous tobramycin antibiotics.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.